Sankyo Company, Limited

Daiichi Sankyo Company, Limited

Snow Brand Milk Products Co., Ltd.

Naohiro Washida

Eisuke Tsuda

Masaaki Goto

Fumie Kobayashi

Kazuki Yano

Kanji Higashio

Tomonori Morinaga

Kyoji Yamaguchi

Nobuyuki Shima

Hisataka Yasuda

Nobuaki Nakagawa

Masahiko Kinosaki

Akihiro Tomoyasu

Ken Takahashi

Yoshiji Yamada

Masatsugu Ueda

Kaoji Higashio

Toshiko Satake

Toshiko Yoshida

Nobuaki Nishiura Heights 2-4 Nakagawa

Tomonori 11-12 Saiwaicho 3-Chome Morinaga

Akihiro Sk-Mansion Tomoyasu

Ken Nishiura Heights 1-4 Takahashi

Eisuke Diapalace Jichiidai 5-Bankan 407 Tsuda

Kazuki Nishiura Heights 3-1 Yano

Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Methods of reducing bone absorption comprising administering an antibody that binds OBM

The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.

Antibodies to OCIF-binding molecules

The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.

Methods for identifying a substance which specifically binds to an osteoclastogenesis inhibitory factor-binding molecule and modulates the biological activity thereof

A method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis characterized by determining the concentration of osteoclastgenesis inhibitory factor (OCIF) in humor. Monoclonal antibodies recognizing equally both of monomer type and dimer type of OCIF. Monoclonal antibodies recognizing selectively dimer type of OCIF. And to provide an assay kit for determination of OCIF concentration comprising the aforementioned two antibodies recognizing different epitope of OCIF and having high affinity showing dissociation constant of less than 2&#xd7;10M with antigen. It is useful for a method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis or for an assay reagent for research thereof.

Method of diagnosing metabolic bone diseases

Method for diagnosing bone dysbolism

Basic osteoblast growth factor II (bOGF-II)

Monoclonal antibodies are provided which specifically bind to human immunoglobulin e (IgE) and has a molecular weight of approximately 150,000 determined by SDS-polyacrylamide gel electrophoresis (non-reduced state), the ability to bind to human IgE-producing B cells, the ability to recognize IgE bound to human or canine cell having Fc.epsilon. receptor and further characterized by specific sequences.

Anti-human IgE monoclonal antibodies

Growing community of inventors

Tochigi, Japan

Naohiro Washida